Featured Trial
Our review committee has reviewed this trial and it meets our criteria for going above and beyond. Learn more about featured trials.
Clinical Trial Goal
To find out if the combination of odronextamab and lenalidomide is safe and works well to treat follicular lymphoma and MZL that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have one of the following that has relapsed or is refractory:
- Follicular lymphoma
- MZL
- Do not have lymphoma in your brain or spinal cord
- Do not have grade 3b follicular lymphoma. Your doctor can tell you this
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Lenalidomide is a drug that blocks growth of cancer cells.
Odronextamab is a bispecific antibody that targets CD20 on certain cells.
Rituximab is a monoclonal antibody that targets CD20 on certain cells.
In this trial, you’ll be randomized to 1 of 2 groups. Once you’re randomized, you’ll be told what group you’re in:
Odronextamab is a bispecific antibody that targets CD20 on certain cells.
Rituximab is a monoclonal antibody that targets CD20 on certain cells.
In this trial, you’ll be randomized to 1 of 2 groups. Once you’re randomized, you’ll be told what group you’re in:
- Group 1 – Odronextamab and lenalidomide
- Group 2 – Rituximab and lenalidomide
Randomized means doctors will use a computer to assign you to either group. A computer assigns you by chance, like flipping a coin or drawing a name out of a hat. You, your doctor or the clinical trial doctor won’t have any control over which group you’ll be assigned. This means you won’t be able to choose your group.
You'll get:
- Lenalidomide –A pill that you take by mouth
- Odronextamab – Group 1 only - Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
- Rituximab - Group 2 only - Given as IV infusions
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 5 years.
The Food and Drug Administration (FDA) has approved rituximab and lenalidomide to treat lymphoma. The FDA has not yet approved odronextamab.
Locations
Sponsors
lead: Regeneron Pharmaceuticals
